Company
Team
CORPORATE GOVERNANCE
Platforms
Glycovirology
Degenerative Diseases
pipeline
ProLectin Pipeline
Degenerative Disease pipeline
Resources
IN THE NEWS
Stroke video
faq
SCIENTIFIC PUBLICATIONS
investors
Company presentation
press releases
Reports
financial
Contact US
$BIXT
Company
Platforms
Glycovirology
Degenerative Diseases
Resources
Investors
Pipeline
contact us
Glycovirology Scientific Publications
featured
Galectin approach to lower covid transmission - Drug Development for clinical use
Galectin approach to lower covid transmission - Drug Development for clinical use
Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection
Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection
Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9
Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9
Previous
load more
Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection
Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection
Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9
Cellular and Molecular Mechanism of Pulmonary Fibrosis Post-COVID-19: Focus on Galectin-1, -3, -8, -9
The Two Nobel Prize Investment
The Two Nobel Prize Investment
Galectin Antagonist use in Mild Cases of SARS-CoV-2: Pilot Feasibility Randomised, Open Label, Controlled Trial
Galectin Antagonist use in Mild Cases of SARS-CoV-2: Pilot Feasibility Randomised, Open Label, Controlled Trial
load more
go back